When Kay Wesley moved from the world of dot com to work as global digital director at AstraZeneca, she realised that pharma was transforming for digital at a rather different pace.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh